The Retina Innovation Showcase  is organized by the OIS community. The program will kick off with hot topics in the retina space followed by a special presentation on novel endpoints, 6 ophthalmic companies presenting their latest clinical data and two lively panel discussions, one clinical and the other industry focused. The program will be concluded with additional networking time. Throughout the event questions can be asked and connections can be made with other participants.

Dr Magali Taiel, Chief Medical Officer, will present GenSight and its latest news about our most advanced product called LUMEVOQ® (GS010), a gene therapy targeting Leber Hereditary Optic Neuropathy (LHON), a rare mitochondiral disease that lead to blindness in young adults. LUMEVOQ® is on track for September 2020 submission in Europe.

You can register for free at the following link: